Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
Phase of Trial: Phase IV
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Iloprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms VENTASTEP
- Sponsors Bayer
- 05 Mar 2018 Planned End Date changed from 31 Mar 2019 to 31 Jul 2019.
- 05 Mar 2018 Planned primary completion date changed from 15 Jan 2019 to 31 Jan 2019.
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.